Crohns Disease
Introduction
Crohn’s
disease is a chronic, recurrent inflammatory disease of the intestinal
tract. The intestinal tract has four major parts: the esophagus, or food
tube; the stomach, where food is churned and broken down; the long
small bowel, where nutrients, calories, minerals and vitamins are
absorbed; and the colon, where water is absorbed, stool is stored and a
good many health benefits occur. The two primary sites for Crohn’s
disease are the last portion of the small bowel (the ileum) and the
colon (Crohn’s colitis). The condition appears to start when the colon’s
normal bacteria stick to the colon’s lining more readily. Normally, the
colon easily fights this off as its immune defenses are so robust and
strong. In Crohn’s Disease, however, this does not occur. Small nests of
inflammation occur, persist and smolder. The inflammation becomes worse
and spreads. The lining of the bowel can then become ulcerated and the
bowel wall thickened. Eventually, the bowel may become narrowed or
obstructed, at which time surgery would be needed.
What Causes Crohn's Disease?
For the most part, Crohn’s Disease is a disorder of young people, even children. There is now evidence of a genetic link as Crohn’s frequently shows up in families and certain ethnic groups. For instance, the disease is more common in Jewish people and less so in African Americans. As noted, there is evidence that the normal healthy bacteria that grow in the lower gut may, in some manner, act to promote inflammation. The body’s immune system, which protects it against many different infections, is a factor.So, a number of clear factors are necessary for Crohn’s Disease to occur.
- There is a genetic link that predisposes some people.
- The colon’s normal bacteria are necessary.
- The colon’s own immune system fails to control the local infection.
Symptoms
The
symptoms of Crohn’s disease depend on where in the intestinal tract the
disorder appears. When the ileum (ileitis) is involved, recurrent pain
may be experienced in the right lower abdomen. At times, the pain mimics
acute appendicitis. When the colon is the site, diarrhea (sometimes
bloody) may occur, along with fever and weight loss. Crohn’s disease
often affects the anal area where there may be a draining sinus tract
called a fistula. When the disease is active, fatigue and lethargy
appear. In children and adolescents there may be difficulty gaining or
maintaining weight. Nutrition and vitamin deficiencies often occur. So,
the main symptoms of Crohn’s Disease may be:
- Recurrent, lower abdominal discomfort
- Failure to gain weight normally, especially in the young
- Chronic fatigue and lethargy
- Bowel urgency and/or diarrhea, sometimes bloody
- Sores or drainage in the anal area
Diagnosis
The diagnosis often begins with a physician’s suspicion that Crohn’s Disease may be present. The patient’s medical history and physical exam are always helpful. Certain blood and stool tests are necessary. X-rays of the small intestine and colon are usually required. In addition, a colonoscopy exam of the entire colon is often the best way of diagnosing the problem. A colonoscopy exam is where the colon is cleaned out and then visually inspected with a lighted endoscope. Biopsy specimens can be obtained. Colonoscopy is usually the definitive exam in making a diagnosis.Course and Complications
The disorder often remains quiet and easily controlled for long periods of time. Most people with Crohn’s disease continue to pursue their goals in life, go to school, marry, raise a family, exercise and work with few limitations or inconveniences.Some problems, outside the bowel, can occur. Arthritis, eye disorders, skin problems, and in rare instances, chronic liver conditions may develop. If the disease occurs around the anal canal, open painful sores called fissures, can develop. A fistula can also form. A fistula is a tiny channel that burrows from the rectum to the skin around the anus. Infrequently, fistulas can track into the urinary bladder, the vagina or even another part of the intestine. In addition, when inflammation persists in the ileum or colon, narrowing and partial obstruction may occur. Surgery is usually required to treat this problem. When Crohn’s disease has been present for many years, there is an increased risk of cancer.
A major problem that may occur very early in the disease is loss of calcium in the bones. This occurs without any symptoms. At this stage, it is called osteopenia. Later, when it progresses, it is called osteoporosis. Since Crohn’s Disease for the most part is a disease of young people, this bone loss can occur at a very early age. This is why most Crohn’s patients need to take extra calcium and vitamin D in their diet and with supplements. In addition, they should get a bone scan (densitometry) to detect early loss of bone. A simple x-ray will not detect early bone loss.
Treatment
Effective medical and surgical treatment is available for Crohn’s disease. It is particularly important to maintain good nutrition with a balanced diet, get adequate exercise, consume adequate vitamins and minerals, especially calcium and vitamin D, and keep a positive, upbeat attitude. Click Crohn’s Dietary Therapy for details. Five types of medications are available to treat this disease.- Cortisone or steroids (prednisone) – These powerful drugs can provide highly effective results. A large dose is often used initially to bring severe disease under quick control. The drug is then tapered to a low maintenance dose, perhaps taken just every other day. Hopefully, the drug may eventually be stopped altogether. Unfortunately, steroids promote calcium loss from bone. This is a major problem for Crohn’s patients. So, early detection and preventative therapy is imperative.
- Anti-inflammation drugs – Sulfasalazine, (Azulfidine, Dipentum, Asacol, Rowasa, Pentasa and Lialda) belong to a group of drugs called the 5-aminosalicylates. These drugs are most useful in maintaining a remission, once the disease is brought under control. They are most effective when the disease is present in the colon and less so for Crohn’s in the small bowel.
- Immune System Suppressors – These medications suppress the body’s immune system, which appears to be overly active and somehow aggravates the disease. The names of two of these commonly used medications are azathioprine (trade name: Imuran) and 6MP (trade name: Purinethol). These drugs are particularly useful for long-term maintenance. There are other potent immune-suppressing drugs that may be used in difficult cases.
- Biologics – These are newer and highly effective compounds that block certain stages of the inflammation. Infliximab (trade name: Remicade) and adalimumab (trade name: Humira) are two such medications.
- Antibiotics – Since there is frequently a bacterial infection along with Crohn’s disease, antibiotics are often used to treat this problem. Two that are commonly used are ciprofloxacin (trade name: Cipro) and metronidazole (trade name: Flagyl).
Dietary Therapy
Dietary therapy for Crohn’s patients is being increasingly recognized as a vital part of overall care. In a real sense, the patient must become an active partner in her or his care. Dietary therapy means that the patient or the caregiver of a patient understands the importance of the following in Crohn’s patients.- Protein – how much and what type
- Carbohydrates – again, how much and what type
- Fat
- Vitamins – especially the importance of C, D and some of the B vitamins
- Minerals – calcium, selenium, zinc
- Fish oil
- Herbs
Fiber, Prebiotics and Probiotics
Fiber in plant food is now known to be especially healthy for everyone’s general health. For Crohn’s Disease patients, fiber can be recommended when the disease is inactive, and especially when there is no narrowing of the bowel, where plant fiber could induce blockage.Soluble prebiotic fibers are a more recently discovered type of fiber, which have some real bowel benefits. Their use in Crohn’s patients is still not certain but since they are simply plant food, there are few side effects. The prebiotic fibers, inulin and oligofructose, are the names of the best studied ones. They promote the growth of good colon bacteria which, in turn, make short chain fatty acids. These fatty acids may be a real benefit to Crohn’s patients as they seem to make bacteria less adherent to the bowel wall and are actually the fuel source for the bowels own cells.
For a full essay on prebiotics, please click here.
A probiotic is a good bacteria or yeast taken by mouth that, hopefully, grows in the colon and produces good results. There is some scientific evidence that probiotics may help some Crohn’s patients. In particular, the use of probiotics and prebiotics together may be appropriate for some. Again, check with your physician.
For a full essay on probiotics, please click here.
Stress and Surgery
Surgery is commonly needed at some time during the course of Crohn’s disease. It may involve removing a portion of diseased bowel, or simply the draining of an abscess or fistula. In all cases, the guiding principle is to perform the least amount of surgery necessary to correct the problem. Surgery does not cure Crohn’s disease.Summary
Most people with Crohn’s disease lead active lives with few restrictions. Although there is no known cure for the disorder, it can be managed with present treatments. There is increased emphasis on patients helping themselves by good dietary management, meaning adequate calories, vitamins, minerals and even prebiotic food fibers and probiotic bacteria. For a few patients, the course of the disease can be complicated, requiring extensive testing and therapy. Surgery sometimes is required. By working closely with your physician and managing your own emotional and dietary behavior, most patients will have a good long term outcome.Medical References
Leenen CH, Dieleman LA; J Nutr. 2007; 137(11 Suppl): P-2572S
Crohn's disease and ulcerative colitis, also called chronic inflammatory bowel diseases (IBD), affect up to 500 per 100,000 persons in the Western world. Recent studies in the etiology of IBD suggest that these diseases are caused by a combination of genetic, environmental, and immunological factors. Results from humans and especially animal models of colitis reported by our group and others have indicated that these diseases result from a lack of tolerance to resident intestinal bacteria in genetically susceptible hosts. Probiotic bacteria have health-promoting effects for the host when ingested and have also shown efficacy in ulcerative colitis and refractory pouchitis. In light of the efficacy of providing probiotic bacteria to patients with IBD, there has been interest in the prophylactic and therapeutic potential of inulin, oligofructose, and other prebiotics for patients with or at risk of IBD. Prebiotics are nondigestible dietary oligosaccharides that affec t the host by selectively stimulating growth, activity, or both of selective intestinal (probiotic) bacteria. Prebiotics are easy to administer and, in contrast to probiotic therapy, do not require administration of large amounts of (live) bacteria and are therefore easier to administer. Studies using prebiotics, especially beta-fructan oligosaccharides, for the treatment of chronic intestinal inflammation have shown benefit in animal models of colitis. Studies using these prebiotics alone or in combination with probiotics are emerging and have shown promise. These dietary therapies could lead to novel treatments for these chronic debilitating diseases.
Hedin C et al; Proc Nutr Soc. 2007; 66(3): P-307-15
Human subjects and their enteric microbiota have evolved together to reach a state of mutual tolerance. Mounting evidence from both animal models and human studies suggests that inflammatory bowel disease (IBD) represents a malfunction of this relationship. The enteric microecology therefore represents an attractive therapeutic target with few side effects. Probiotics and prebiotics have been investigated in clinical trials as treatments for IBD, with conflicting results. The evidence for the use of probiotics in the management of pouchitis is persuasive and several studies indicate their effectiveness in ulcerative colitis. Trials of probiotics and prebiotics in Crohn's disease are less convincing. However, methodologies vary widely and a range of probiotic, prebiotic and combination (synbiotic) treatments have been tested in a variety of patient groups with an assortment of end points. Conclusions about any one treatment in a specific patient group can therefore only be drawn on evidence from relatively small numbers of patients. The present article reviews the role of the intestinal microbiota in the pathogenesis of IBD and addresses the clinical evidence for the therapeutic manipulation of bowel microbiota using probiotics, prebiotics and synbiotics in IBD.
Lindsay JO et al; Gut. 2006; 55(3): P-348-55
BACKGROUND AND AIMS: The intestinal microbiota play a pivotal role in the inflammation associated with Crohn's disease through their interaction with the mucosal immune system. Some bifidobacteria species are immunoregulatory and induce increased dendritic cell interleukin 10 (IL-10) release in vitro. Fructo-oligosaccharides (FOS) increase faecal and mucosal bifidobacteria in healthy volunteers. The aim of this study was to assess the effect of FOS administration on disease activity, bifidobacteria concentrations, and mucosal dendritic cell function in patients with moderately active Crohn's disease. PATIENTS AND METHODS: Ten patients with active ileocolonic Crohn's disease received 15 g of FOS for three weeks. Disease activity was measured using the Harvey Bradshaw index. Faecal and mucosal bifidobacteria were quantified by fluorescence in situ hybridisation, and mucosal dendritic cell IL-10 and Toll-like receptor (TLR) expression were assessed by flow cytometry of dissociated rectal biopsies. RESULTS: FOS induced a significant reduction in the Harvey Bradshaw index from 9.8 (SD 3.1) to 6.9 (3.4) (p < 0.01). There was a significant increase in faecal bifidobacteria concentration from 8.8 (0.9) log(10) to 9.4 (0.9) log(10) cells/g dry faeces (p < 0.001). The percentage of IL-10 positive dendritic cells increased from 30 (12)% to 53 (10)% (p=0.06). Finally, the percentage of dendritic cells expressing TLR2 and TLR4 increased from 1.7 (1.7)% to 36.8 (15.9)% (p=0.08) and from 3.6 (3.6)% to 75.4 (3.4)% (p < 0.001), respectively. CONCLUSIONS: FOS supplementation increases faecal bifidobacteria concentrations and modifies mucosal dendritic cell function. This novel therapeutic strategy appears to decrease Crohn's disease activity in a small open label trial and therefore warrants further investigation.
Article printed from Jackson GI: http://www.jacksongi.com
URL to article: http://www.jacksongi.com/disease/crohns-disease/
Click here to print.